Letter

Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency

BMJ 2006; 332 doi: 10.1136/bmj.332.7555.1451-b (Published 15 June 2006)
Cite this as: BMJ 2006;332:1451.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Enrique J Sánchez-Delgado, professor (esanchez@metropolitano.com.ni)
  1. Hospital Metropolitano Vivian Pellas, Managua, Nicaragua

    EDITOR—The paper by Kearney et al on the risk of atherothrombosis with cyclo-oxygenase-2 (COX 2) inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs) supports the data of Hippisley-Cox et al, who revised the gastrointestinal risks of these drugs.1 2


    Embedded Image

    A clear picture is forming, that the risks and benefits are determined by doses and potencies more than by their selectivity to the cyclo-oxygenases, with the exception of low dose aspirin, which permanently inhibits platelet …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular